Mounjaro is a highly effective, UK-licensed weight loss treatment, proven in clinical trials to support approximately 20% body weight reduction. It is the latest GLP-1 weight loss injection and is prescribed for individuals with a body mass index (BMI) over 30 or those with a BMI of 28 who have a weight-related medical condition.
The active ingredient in Mounjaro is Tirzepatide, a registered trademark of Eli Lilly. In the US, it is marketed as Zepbound, but it is available in the UK under the brand name Mounjaro.
Mounjaro is administered once weekly as a subcutaneous (under the skin) injection. Detailed instructions on how to use it can be found in the Patient Information Leaflet provided with the medication.